BioPharm International
January 01, 2020
Cover Story
33
1
Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.
January 01, 2020
From the Editor
33
1
The promise of new therapies is tempered by the need for affordability, safety, and ethics.
January 01, 2020
Manufacturing
33
1
While cell and gene therapies differ in many ways, some of the best practices for process development and validation are similar.
January 01, 2020
Special Coverage
33
1
With a positive employment market, some biopharma professionals explore options for career advancement.
January 01, 2020
Regulatory Beat
33
1
Pressures on FDA will affect industry’s success in bringing new therapies to market.
January 01, 2020
Downstream Processing
33
1
Temperature-sensitive biologics are lyophilized to preserve therapeutic viability, but the process presents complexities and challenges that are as yet not fully understood.
January 01, 2020
Upstream Processing
33
1
Industry experts debate the pros and cons of “going bigger” than the 2000-L industry norm in a single vessel.
January 01, 2020
Peer-Reviewed Research
33
1
This study aims to use plant-leaf extract for the green synthesis of gold nanoparticles and to evaluate their antibacterial and antioxidant activity.
January 01, 2020
Quality/Regulations
33
1
Focusing on symptoms instead of root causes locks teams into a corrective, rather than preventive, mindset.
January 01, 2020
Issue PDF
33
1
Click the title above to open the BioPharm International January 2020 issue in an interactive PDF format.